WO2023043868A3 - Coronavirus vaccine, yeast strains, methods of detection, methods of treatment and uses thereof - Google Patents

Coronavirus vaccine, yeast strains, methods of detection, methods of treatment and uses thereof Download PDF

Info

Publication number
WO2023043868A3
WO2023043868A3 PCT/US2022/043578 US2022043578W WO2023043868A3 WO 2023043868 A3 WO2023043868 A3 WO 2023043868A3 US 2022043578 W US2022043578 W US 2022043578W WO 2023043868 A3 WO2023043868 A3 WO 2023043868A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
detection
treatment
vaccine
yeast strains
Prior art date
Application number
PCT/US2022/043578
Other languages
French (fr)
Other versions
WO2023043868A2 (en
Inventor
Tommy Idrovo Hidalgo
Lorena Itati IBAÑEZ
Natalia Brenda Fernandez
Javier Santos
Cecilia D'ALESSIO
Alejandro Daniel Nadra
Florencia Pignataro
Original Assignee
Consejo Nacional De Investigaciones Científicas Y Técnicas (Conicet)
Universidad De Buenos Aires (Uba)
Inis Biotech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Nacional De Investigaciones Científicas Y Técnicas (Conicet), Universidad De Buenos Aires (Uba), Inis Biotech Llc filed Critical Consejo Nacional De Investigaciones Científicas Y Técnicas (Conicet)
Publication of WO2023043868A2 publication Critical patent/WO2023043868A2/en
Publication of WO2023043868A3 publication Critical patent/WO2023043868A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention refers to a vaccine and a method to obtain coronavirus antibodies, yeast strains, methods of detection, methods of treatment and uses thereof. A coronavirus vaccine comprising the deglycosylated RBD domain of the coronavirus spike protein and one or more adjuvants, wherein the RBD domain is produced in P. pastoris. Among others, the amino acid sequence of the RBD domain may be the sequence set forth in SEQ ID NO. 1 or SEQ ID NO. 2, wherein the vaccine may further comprise one or more adjuvants.
PCT/US2022/043578 2021-09-16 2022-09-15 Coronavirus vaccine, yeast strains, methods of detection, methods of treatment and uses thereof WO2023043868A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ARP20210102579 2021-09-16
ARP210102579A AR123532A1 (en) 2021-09-16 2021-09-16 CORONAVIRUS VACCINE, YEAST STRAINS, DETECTION METHODS, TREATMENT METHODS AND USES

Publications (2)

Publication Number Publication Date
WO2023043868A2 WO2023043868A2 (en) 2023-03-23
WO2023043868A3 true WO2023043868A3 (en) 2023-10-12

Family

ID=84578120

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/043578 WO2023043868A2 (en) 2021-09-16 2022-09-15 Coronavirus vaccine, yeast strains, methods of detection, methods of treatment and uses thereof

Country Status (2)

Country Link
AR (1) AR123532A1 (en)
WO (1) WO2023043868A2 (en)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111920946A (en) * 2020-08-07 2020-11-13 合肥诺为尔基因科技服务有限公司 Cyclic dinucleotide modified aluminum nanoparticle vaccine adjuvant-delivery system and SARS-CoV-2 subunit vaccine based on the same
WO2021002776A1 (en) * 2020-04-23 2021-01-07 Federal State Budgetary Institution "National Research Centre For Epidemiology And Microbiology Named After The Honorary Academician N.F. Gamaleya" Of The Ministry Of Health Of The Russian Federation Immunobiological agent for inducing specific immunity against severe acute respiratory syndrome virus sars-cov-2
US20210079366A1 (en) * 2017-12-22 2021-03-18 The Broad Institute, Inc. Cas12a systems, methods, and compositions for targeted rna base editing
US20210206810A1 (en) * 2019-11-20 2021-07-08 Ingenza Ltd. Detection of Optimal Recombinants Using Fluorescent Protein Fusions
US20210236624A1 (en) * 2018-06-12 2021-08-05 Kentucky Bioprocessing, Inc. Vaccines formed by virus and antigen conjugation
WO2021169255A1 (en) * 2020-02-24 2021-09-02 成都威斯克生物医药有限公司 Anti-sars-cov-2 infection protein and vaccine
US20210275665A1 (en) * 2020-03-05 2021-09-09 Iowa State University Research Foundation, Inc. IMMUNOGENIC AND VACCINE COMPOSITIONS AGAINST SARS-CoV-2

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210079366A1 (en) * 2017-12-22 2021-03-18 The Broad Institute, Inc. Cas12a systems, methods, and compositions for targeted rna base editing
US20210236624A1 (en) * 2018-06-12 2021-08-05 Kentucky Bioprocessing, Inc. Vaccines formed by virus and antigen conjugation
US20210206810A1 (en) * 2019-11-20 2021-07-08 Ingenza Ltd. Detection of Optimal Recombinants Using Fluorescent Protein Fusions
WO2021169255A1 (en) * 2020-02-24 2021-09-02 成都威斯克生物医药有限公司 Anti-sars-cov-2 infection protein and vaccine
US20210275665A1 (en) * 2020-03-05 2021-09-09 Iowa State University Research Foundation, Inc. IMMUNOGENIC AND VACCINE COMPOSITIONS AGAINST SARS-CoV-2
WO2021002776A1 (en) * 2020-04-23 2021-01-07 Federal State Budgetary Institution "National Research Centre For Epidemiology And Microbiology Named After The Honorary Academician N.F. Gamaleya" Of The Ministry Of Health Of The Russian Federation Immunobiological agent for inducing specific immunity against severe acute respiratory syndrome virus sars-cov-2
CN111920946A (en) * 2020-08-07 2020-11-13 合肥诺为尔基因科技服务有限公司 Cyclic dinucleotide modified aluminum nanoparticle vaccine adjuvant-delivery system and SARS-CoV-2 subunit vaccine based on the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BARRERO JUAN J., CASLER JASON C., VALERO FRANCISCO, FERRER PAU, GLICK BENJAMIN S.: "An improved secretion signal enhances the secretion of model proteins from Pichia pastoris", MICROBIAL CELL FACTORIES, vol. 17, no. 1, 1 December 2018 (2018-12-01), XP093100754, DOI: 10.1186/s12934-018-1009-5 *

Also Published As

Publication number Publication date
AR123532A1 (en) 2022-12-14
WO2023043868A2 (en) 2023-03-23

Similar Documents

Publication Publication Date Title
RU2221045C2 (en) Haemophilus influenzae antigen omp26, nucleic acid encoding it and its using
SI2340038T1 (en) Biochemically stabilized hiv-1 env trimer vaccine
WO2022043551A3 (en) Multivalent nucleic acid based coronavirus vaccines
ATE153380T1 (en) METHOD FOR OBTAINING NATURAL, OLIGOMERIC, GLYCOSYLATED ECTODOMAIN VIRAL MEMBRANE PROTEINS, THEIR USE, IN PARTICULAR AS A VACCINE AGAINST HIV
WO2006123256A3 (en) Hivcon: an hiv immunogen and uses thereof
WO2018193063A3 (en) Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to
WO2021159118A8 (en) Composition and method of mrna vaccines against novel coronavirus infection
WO2023042099A3 (en) Vaccines for coronavirus prevention and treatment
WO2002004496A3 (en) Fimh adhesin proteins and methods of use
EP4295902A3 (en) Probiotic bacterial strains producing antimicrobial proteins and compositions comprising these for use in the treatment of clostridium difficile infection
MY131143A (en) Proteins derived from white spot syndrome virus and uses thereof
WO2003059385A3 (en) Hiv vaccine and method of use
WO2023043868A3 (en) Coronavirus vaccine, yeast strains, methods of detection, methods of treatment and uses thereof
WO2023147092A3 (en) Coronavirus vaccine
WO2021216876A3 (en) Antibodies to coronavirus spike protein and methods of use thereof
WO2003004683A3 (en) Nucleic acids encoding recombinant 56 and 82 kda antigens from gametocytes of eimeria maxima and their uses
WO2022103929A3 (en) Nucleic acids, proteins, and vaccines of sars-cov-2
WO2006109174A3 (en) Hiv vaccine comprising a glycoprotein 120 signal sequence with no more than one positively charged amino acid
WO2009130256A3 (en) Tat protein for preventing or treating aids
WO2010128364A1 (en) Method for the prevention or treatment of taxodiaceae pollen allergy
ATE454394T1 (en) RECOMBINANT 250 KDA ANTIGEN FROM EIMERIA MAXIMA SPOROZOITES/MEROZOITES ENCODING NUCLEIC ACIDS AND USES THEREOF
WO2022187230A3 (en) Methods and compositions for detecting and producing porcine morbillivirus and immunogenic compositions thereof
ATE491466T1 (en) COMPOSITIONS FOR TRIGGERING AN IMMUNE REACTION AGAINST THE PARATUBERCULOSIS SUBSPECIES OF MYCOBACTERIUM AVIUM
WO1998040497A3 (en) An ex vivo animal or challenge model as method to measure protective immunity directed against parasites and vaccines shown to be protective in said method
WO2005012339A3 (en) Immunogenic protein and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22870656

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2022870656

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022870656

Country of ref document: EP

Effective date: 20240416